Gamma-delta T cells in neuroblastoma: Exploiting MHC-independent recognition to overcome the barriers of high-risk disease
Neuroblastoma is the most frequent extracranial solid tumor in children and the main cause of early childhood cancer deaths. Relapse occurs in more than half of high-risk patients despite rigorous multimodal therapy, and four-year overall survival in relapsed disease is approximately 20%. Anti-GD2 monoclonal antibodies and GD2-directed CAR T cell treatment have advanced the field, although neither has eliminated neuroblastoma's immune resistance. Current immunotherapy has three interrelated challenges. GD2 heterogeneity lets antigen-negative subclones escape and cause recurrence. Inhibitory cytokines, regulatory T cells, and myeloid-derived suppressor cells dominate the TME. MHC class I downregulation frequently renders traditional αβ T cell methods ineffective, even with the target antigen present. Gamma-delta (γδ) T cells offer a distinct mechanism. They recognize tumor targets without antigen presentation by sensing stress-induced ligands through NKG2D and DNAM-1 and phosphoantigens through butyrophilin proteins BTN3A1 and BTN2A1. This recognition holds regardless of MHC class I status. In conjunction with anti-GD2 antibodies, CD16 expression boosts antibody-dependent cellular cytotoxicity. In neuroblastoma lesions, γδ T cells are the primary antitumoral fraction in tumor-infiltrating lymphocyte products, indicating compatibility with the disease's immune system. This study examines neuroblastoma immunotherapy failure mechanisms and innovative γδ T cell platforms, such as non-engineered allogeneic products, composite γδ T plus NK cell techniques, and CAR- and AbTCR-modified designs. A biomarker-driven patient selection paradigm and product standardization, in vivo persistence, and TME suppression are examined. NCT05400603, the first trial of adoptive transfer of ex vivo-expanded allogeneic γδ T cells in a population that includes pediatric neuroblastoma patients, is crucial for proving the mechanism.
Authors
- Zahra Karimizadeh (ORCID: https://orcid.org/0000-0002-9658-6354)
- Amirali Kalantari (ORCID: https://orcid.org/0009-0005-2629-1832)
- Samira Mohamadian (ORCID: https://orcid.org/0009-0001-2500-4775)
- Maryam Behfar (ORCID: https://orcid.org/0000-0001-9473-3632)
- Amir Ali Hamidieh (ORCID: https://orcid.org/0000-0002-8935-079X)
- Hamid Farajifard (ORCID: https://orcid.org/0000-0002-4500-5855)
- Rashin Mohseni (ORCID: https://orcid.org/0000-0003-2452-9163)
- Nafiseh Esmaeil (ORCID: https://orcid.org/0000-0001-7237-1984)
- Mitra Ardakani Moghadam
Institutions
- Isfahan University of Medical Sciences (IR)
- Children's Medical Center (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Translational Oncology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1016/j.tranon.2026.103122
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00